The clock is ticking on Tesla's mysterious new cheaper models

Tesla is gearing up to finally launch its robotaxi service, but the company is drawing close to another equally important deadline.
As Elon Musk gets set to begin offering robotaxi rides to a select group of invitees in Austin this weekend, Tesla fans are still waiting for news about the company's long-awaited low-cost electric cars.
In January, Tesla said that it would start production on new models, "including more affordable models," in the first half of 2025.
In the automaker's earnings in April, Tesla reiterated this timeline, with Vice President of Vehicle Engineering Lars Moravy saying the company was working through "last-minute issues" on the new cars.
That deadline is fast approaching, and there is little sign that Tesla is gearing up for a major product launch.
The stakes for the EV giant are high. Tesla has seen its sales collapse across the globe so far this year, as it grapples with consumer backlash over CEO Musk's politics and production disruptions due to a refresh of its best-selling Model Y EV.
Analysts previously told Business Insider that Tesla's stale product lineup is not helping matters. The carmaker has not launched a new vehicle since the Cybertruck in 2023, and the angular pickup's sales have been underwhelming.
Even as Tesla's product lineup has stagnated, its rivals have launched a flurry of new electric models. Much of this competition has come from China, where a brutally competitive EV market has pushed Chinese companies like BYD to launch new models at rock-bottom prices.
Data from industry group EV Volumes found that although Tesla's Model Y and 3 were still the top-selling electric cars in the world in the first four months of the year, their sales are coming under pressure from BYD's Seagull and the Wuling Mini, two affordable, compact city cars that sell for the equivalent of less than $10,000 in China.
Fears grow over fundamentals
Some analysts have already begun to sound the alarm bells.
In a note this week, Wells Fargo analysts Colin Langan and Kosta Tasoulis said that Tesla's business fundamentals were worse than expected, with deliveries failing to recover in the second quarter.
The analysts also warned that the recent Senate ruling to end California's zero-emission rules would remove the need for automakers to buy regulatory credits from Tesla, which they estimated could cut Tesla's earnings before tax and interest by as much as 16%.
Langan and Tasoulis said demand for the refreshed Model Y, which Tesla began rolling out earlier this year, "appears weak," adding that the mysterious affordable models were the only apparent driver of sales in the second half of the year.
Despite their importance, it's still unclear what the new models hinted at by Tesla will look like.
Tesla has said they will be produced on the same manufacturing lines as its current vehicles and will use aspects of the same platform.
Reuters has reported that the new models will include a stripped-down version of the Model Y, production of which has been delayed by several months, according to anonymous sources.
For now, it seems Musk and Tesla are mostly focused on the 10 or so robotaxis set to launch in Austin, leaving a major question mark over the rest of the company's product roadmap.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Associated Press

14 minutes ago

• Associated Press

ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

New York, New York--(Newsfile Corp. - June 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the 'Class Period'), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased PepGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the PepGen class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) PGN-EDO51 was less effective and safe than defendants had led investors to believe; (2) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ('FDA') approval; (3) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-ED051's clinical, regulatory, and commercial prospects were overstated; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the PepGen class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit

Associated Press

14 minutes ago

• Associated Press

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

New York, New York--(Newsfile Corp. - June 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the 'Class Period'), of the important August 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Rocket Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Rocket Pharmaceuticals class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events ('SAEs'), including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused shareholders to purchase Rocket Pharmaceuticals securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Rocket Pharmaceuticals class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit

Yahoo

42 minutes ago

• Yahoo

Robotaxis Could Redefine Tesla or Rattle Its Stock

Tesla's (NASDAQ:TSLA) much-anticipated robotaxi pilot, set to roll out June 22 in Austin, is pivotal for the company's next growth chapter. Success could redefine its revenue model; failure could dent valuation and long-term prospects. Jacob Falkencrone, Saxo's global head of investment strategy, warns that the launchElon Musk's next trillion-dollar chapteris as much about regulatory navigation as true autonomy. Roughly ten Model Y robotaxis running Tesla's Full Self-Driving software will operate in geo-fenced zones under remote human oversight, reflecting cautious, phased deployment rather than a turnkey self-drive revolution. Skepticism lingers amid Democratic lawmakers urging a delay until new Texas safety laws kick in on September 1, and an ongoing NHTSA probe into Tesla's autonomous systems. Historically, Tesla share prices spike on hype and retreat on reality. A smooth pilot could position Tesla as a mobility services leader, slashing urban travel costs by up to 70% and potentially eclipsing its core car-sales business. Conversely, any misstepsregulatory pushback, tech hiccups, or safety incidentscould spook investors and create tactical buying windows. Early user feedback, regulatory responses, and incident reports will be key barometers. Investors should watch those signals closely to gauge whether robotaxis truly deliver transformative upside or morph into another Musk-driven mirage. This article first appeared on GuruFocus.